MeSH

An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Year introduced: 1998

used to treat ulcerative colitis

Date introduced: February 20, 2009

a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source

Date introduced: August 11, 1983

A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)

Year introduced: 1995 (1963)

a hydrogen sulfide-releasing derivative of mesalamine that exerts antinociceptive effects in a model of postinflammatory hypersensitivity; structure in first source

Date introduced: October 30, 2006

structure in first source

Date introduced: September 17, 2001

a mesalamine prodrug; structure in first source

Date introduced: April 14, 2017